[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse BMP1

Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus, trans-Golgi network Secreted, extracellular space, extracellular matrix Note=Co-localizes with POSTN in the Golgi.
Domain PF01400 Astacin (Peptidase family M12A)
PF00431 CUB domain
PF07645 Calcium-binding EGF domain
Function

Cleaves the C-terminal propeptides of procollagen I, II and III. Induces cartilage and bone formation. May participate in dorsoventral patterning during early development by cleaving chordin (CHRD). Responsible for the proteolytic activation of lysyl oxidase LOX.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001502 cartilage condensation
GO:0001503 ossification
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030509 BMP signaling pathway
GO:0042157 lipoprotein metabolic process
GO:0043062 extracellular structure organization
GO:0048705 skeletal system morphogenesis
GO:0051216 cartilage development
GO:0060389 pathway-restricted SMAD protein phosphorylation
GO:0060393 regulation of pathway-restricted SMAD protein phosphorylation
GO:0060395 SMAD protein signal transduction
GO:0061035 regulation of cartilage development
GO:0061036 positive regulation of cartilage development
GO:0061448 connective tissue development
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0098743 cell aggregation
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005160 transforming growth factor beta receptor binding
GO:0008083 growth factor activity
GO:0008236 serine-type peptidase activity
GO:0008237 metallopeptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2214320: Anchoring fibril formation
R-HSA-2022090: Assembly of collagen fibrils and other multimeric structures
R-HSA-1650814: Collagen biosynthesis and modifying enzymes
R-HSA-1474290: Collagen formation
R-HSA-2243919: Crosslinking of collagen fibrils
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
R-HSA-194223: HDL-mediated lipid transport
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BMP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BMP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BMP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7110.0494
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4340.486
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1770.902
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1610.72
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2640.906
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0240.994
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0890.851
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3060.836
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.090.958
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9810.532
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9570.369
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2920.0273
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BMP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.16.84.30.443
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.16.84.30.673
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BMP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BMP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BMP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BMP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BMP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BMP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBMP1
Namebone morphogenetic protein 1
Aliases procollagen C-endopeptidase; PCOLC; OI13; TLD; mammalian tolloid protein; procollagen C-proteinase 3; Procol ......
Chromosomal Location8p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BMP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.